Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ambrose Panico

Clinical Cardiac Electrophysiology Mesa, AZ Doctor of Osteopathy

NPI 1245539659 CMS profile 626501

6309 E Baywood Ave Ste 101, Mesa, AZ 85206

Open in the dashboard

General payments

$107,755

707 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$254,902 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Ambrose Panico of Mesa, AZ is reported in the CMS Open Payments database as having received $107,755 across 707 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $254,902 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,557 152
2024 General $25,997 194
2023 General $29,520 155
2022 General $16,764 102
2021 General $2,038 52
2020 General $1,954 20
2019 General $12,925 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ambrose Panico
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Ambrose Panico were reported at $18,557. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Ambrose Panico Clinical Cardiac Electrophysiology median Middle half National median
2019 $12,925 $2,361 $585–$8,260 $163
2020 $1,954 $993 $247–$4,351 $114
2021 $2,038 $1,185 $326–$4,739 $132
2022 $16,764 $2,073 $554–$6,789 $149
2023 $29,520 $2,568 $759–$8,159 $160
2024 $25,997 $2,557 $703–$7,403 $164
2025 $18,557 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Impulse Dynamics (USA) Inc. $32,687 99 payments
  2. Biosense Webster, Inc. $19,405 156 payments
  3. Sanofi-Aventis U.S. LLC $14,162 14 payments
  4. Boston Scientific Corporation $10,682 87 payments
  5. Abbott Laboratories $8,202 99 payments
  6. Medtronic Vascular, Inc. $6,715 8 payments
  7. Medtronic, Inc. $5,204 40 payments
  8. Kestra Medical Technology Services, Inc. $3,533 14 payments
  9. AOP Health US, LLC $942 1 payment
  10. Medical Device Business Services, Inc. $750 1 payment
  11. Other $5,472 188 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $30,702 637 payments
  2. Honoraria $23,200 11 payments
  3. Consulting Fee $15,500 10 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,152 4 payments
  5. Grant $12,650 3 payments
  6. Travel and Lodging $10,100 36 payments
  7. Education $411 5 payments
  8. Long term medical supply or device loan $39 1 payment
Products named General payments · program years 2019–2025
  1. OPTIMIZER Cardiovascular Device $17,919 72 payments
  2. OPTIMIZER Cardiovascular Device $17,919 72 payments
  3. Optimizer Cardiovascular $14,695 25 payments
  4. Carto 3 $14,123 82 payments
  5. Optimizer Cardiovascular $12,644 22 payments
  6. GENERAL BRADY $5,000 1 payment
  7. AVEIR $3,616 16 payments
  8. Assure WCD $3,397 12 payments
  9. GENERAL - BRADY $1,400 1 payment
  10. ENSITE $1,064 12 payments
  11. Other $20,031 455 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

3,030

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,050,514

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

42.2%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 491 $584,297
Xarelto Rivaroxaban Brand 139 $179,559
Entresto Sacubitril/Valsartan Brand 85 $112,561
Multaq Dronedarone Hcl Brand 59 $76,279
Farxiga Dapagliflozin Propanediol Brand 31 $35,938
Corlanor Ivabradine Hcl Brand 28 $15,636
Flecainide Acetate Generic 103 $5,821
Sotalol Sotalol Hcl Brand 170 $4,978
Amiodarone Hcl Generic 122 $4,187
Dofetilide Generic 13 $3,286

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$522,115

Medicare's payments for the services billed

Medicare patients

1,238

Average age 78

Services billed

8,225

567 women, 671 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 62%
Ischemic heart disease 50%
Arthritis 49%
Heart failure 46%
Chronic kidney disease 40%
Diabetes 33%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
$133 — —
JARDIANCE
$102 — —
MULTAQ
$61 59 —
CAMZYOS
$49 — —
VERQUVO
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

707 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record